# Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

> **NCT01626248** · — · COMPLETED · sponsor: **John F. Foley, MD** · enrollment: 164 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01626248
- **Lead sponsor:** John F. Foley, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-04
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2013-06-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626248, "Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01626248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*